Yale University: 'Paradigm-shifting' Treatment for Pediatric Diabetes Cleared by FDA
June 27, 2026
June 27, 2026
NEW HAVEN, Connecticut, June 27 -- Yale University issued the following news:
* * *
'Paradigm-shifting' treatment for pediatric diabetes cleared by FDA
Yale's Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab -- recently approved for pediatric patients with Stage 3 Type 1 diabetes -- delays the progression of the disease.
By Meg Dalton
For more than 30 years, Yale e . . .
* * *
'Paradigm-shifting' treatment for pediatric diabetes cleared by FDA
Yale's Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab -- recently approved for pediatric patients with Stage 3 Type 1 diabetes -- delays the progression of the disease.
By Meg Dalton
For more than 30 years, Yale e . . .